8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 16, 2014

GENSPERA, INC.

(Exact name of registrant as specified in Charter)

Delaware	0001421204	20-0438951
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(IRS Employee Identification No.)

2511 N Loop 1604 W, Suite 204

San Antonio, TX 78258

(Address of Principal Executive Offices)

210-479-8112

(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On April 16, 2014, GenSpera, Inc. (the “Company”) released an updated corporate overview on its website www.genspera.com. Filed herewith as Exhibit 99.01 is the corporate overview.

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in the exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01     Financial Statement and Exhibits.

Exhibit Number	Description
99.01	GenSpera corporate overview

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 16, 2014

GenSpera, Inc.
By:	/s/ Craig Dionne
	Craig Dionne Chief Executive Officer

INDEX OF EXHIBITS

Exhibit Number	Description
99.01	GenSpera corporate overview

EX-99.01

Corporate Overview April 2014 OTCQB : GNSZ

2 Safe Harbor Statement Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 : Any statements that are not historical facts are forward - looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward - looking statements, which may include, but are not limited to, factors related to GenSpera's anticipated growth strategies, the outcome of its clinical trials, future business development, ability to develop new products, expand to other related industries or markets in other geographical locations, and other information detailed from time to time in the Company's filings and future filings made with the United States Securities and Exchange Commission . Readers are advised that this information is intended for the use of investment professionals . Anyone interested in obtaining information on GenSpera should contact GenSpera directly . This presentation was developed by GenSpera and is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company's stock . This presentation is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete . Opinions expressed herein are those of management as of the date of the presentation and are subject to change without notice .

3 GenSpera Investment Profile • GenSpera is a leader in developing prodrug therapeutics for the treatment of cancer • Unique, naturally derived, cancer killing drug has advantages in potency and significantly reduced side - effects • Experienced scientific and development team • Robust global IP position • G - 202, GenSpera’s lead candidate, is showing excellent clinical results • Only a few easily managed and predictable side effects seen in Phase 1 • Phase 1B and early Phase 2 data in liver cancer are highly suggestive of clinical activity. • Multiple development opportunities based on our prodrug platform • Four drug candidates in the pipeline • Targeting three large and deadly global cancers that currently have poor or inadequate treatment options

4 Opportunity • Both traditional and emerging treatments for many late stage cancers struggle with issues of potency and/or side effects » In general, the more potent the drug, the worse the side effects Traditional Chemotherapies Serious side effects, resistance, little effect on slowly - dividing cancer cells Antibody Drug Conjugates Target high antigen expressing cells, lower probability of complete tumor kill Anti - Angiogenics Limited survival benefit, serious side - effects GenSpera’s Prodrug Technology Platform Utilizes a highly potent agent Masks its toxicity in the blood stream Delivers and activates it only at the tumor site

5 Novel Technology Platform 12ADT Prodrug • Thapsigargin - the active ingredient isolated from Thapsia garganica • Well characterized toxin that kills both slow - and fast - growing cancer cells • Effective potency is 10 - 100x greater than common cytotoxic agents Creating our Prodrug Extraction and chemical modification • Our toxic “payload” is inactive and soluble in the blood stream. • Different peptides are used to target different tumor sites. • Active drug is released via removal of the targeting peptide only at the tumor site. Masking and targeting peptide attached

6 RESEARCH PRE - CLINICAL PHASE 1 PHASE 2 Liver Cancer (HCC) GenSpera Clinical Programs Evaluating Multiple Oncology Indications TARGET SITE DRUG INDICATION Brain Cancer (GBM) Prostate cancer (PCa) Prostate cancer (PCa) Prostate cancer(PCa) Prostate cancer (PCa) G - 202 Blood vessels of most solid tumors Surface of all prostate cancer cells G - 114 G - 301 G - 115 DEVELOPMENT STAGE HUMAN CLINICAL TRIALS Over $20M deployed by GenSpera to advance its clinical programs Over $15M of grant funded research at Johns Hopkins PHASE 3 16 patients treated in Ph2 study at 5 sites 3 patients enrolled in Ph2 study at UCSD* Ph2 to begin Q2 2014 at UTHSC Houston* Efficacy in animal models Efficacy in animal models Pilot toxicology complete * Ph2 costs primarily supported by investigator funds

7 GenSpera Clinical Programs Focus on G - 202 as Lead Drug Candidate • G - 202 ’s masking/targeting peptide is cleaved by the enzyme PSMA • Initially, PSMA was thought to be found only on the surface of prostate cancer cells • Later, PSMA was found to also be expressed in the vasculature of most tumors , but not in most other tissues or the vasculature of normal tissue » G - 202 is expected to be useful against many tumor types • Animal studies with G - 202 showed excellent results for multiple cancer models • Tolerance of intense dosing regimens, and no drug resistance observed • Dramatic and uniform response even with short dosing regimens • Tumor regression in many cases » Lead drug candidate for clinical development

8 G - 202 Phase I Results Evaluating Safety • Data on 44 patients in trials at Johns Hopkins, University of Wisconsin and UTHSC San Antonio • IV infusion of G - 202 in escalating doses on Days 1, 2, 3 of 28 - day schedule Phase 1 and Phase 1b trials Results » Highly encouraging safety profile • Easily managed, predictable, side effects • Fatigue, nausea on Day 1, and transient rash and/or elevation of serum creatinine • No apparent effect on liver or cardiovascular system • No apparent affect on bone marrow

9 G - 202 Phase 2 Studies Targeting Large and Deadly Global Cancers • Most common liver cancer • 6th most prevalent type of cancer; 750,000 annual incidence worldwide • 3rd highest mortality • Most common type of primary brain malignancy; 10,000 new cases annually in US • Most frequently diagnosed cancer in men in the US; ~240,000 new cases each year Hepatocellular Carcinoma (HCC) Glioblastoma multiforme (GBM) Prostate Cancer (PCa) Incidence Market Potential Therapy snapshot Particularly high PSMA expression in tumor vasculature High PSMA expression in tumor • Only one approved drug (Nexavar®); provides ~2 months increase in median survival with significant side effects • Projected market over $1.5B by 2019 • Avastin® provides increase in median survival of ~ 4 months • Avastin® projected sales in GBM of $460M in 2017 • Viewed as stepping - stone to breast & lung cancer metastases to brain – 10 - fold larger market with little competition • Currently projected to be dominated by anti - hormonal treatments with significant side effects • Anticipated market of > $6.7 B by 2020

10 HCC Competitive Landscape • Nexavar® • Cabozantinib • Regorafenib • Ramucirumab • Tivantinib • Lenvatinib • Kinase Inhibitor • Kinase Inhibitor • Approved • ~2mo increase in median survival • Significant • Phase 3 • Median PF* survival: 4.4 mo • Significant • Kinase Inhibitor • Phase 3 • Median Time to Progression: 4.3 mo • Significant • Anti - VEGFR • Phase 3 • Median PF* Survival: 4.0 mo • Significant • C - Met Inhibitor • Phase 3 • Median Time to Progression: 1.6 mo • Significant • Kinase Inhibitor • Approved • Median Time to Progression: 3.7 mo • Significant DRUG TYPE STATUS INDICATORS OF EFFICACY SIDE EFFECTS * Progression Free Following from Phase 2 Data Poor Efficacy and Significant Side Effects

11 G - 202 Phase IB and 2 Emerging Results Highly Suggestive of Clinical Activity for HCC • Studies treat patients with progressive advanced HCC following failure of Nexavar® therapy • Phase 1B study of 5 patients was quite encouraging: • Treated an additional 16 patients to date in a subsequent Phase 2 study • Data not yet mature, with most patients coming onto the study in just the last few months. However, from a combination of Phase 1B and Phase 2 data we can say: » Over 70% of patients are exhibiting disease stabilization (tumor not progressing) » One patient has had a total of 16 treatment cycles over a 20 month period » End of bone pain and decreased tumor size in patient with vertebral metastasis Time to Progression (TTP) in Months 1 2 3 4 5 6 7 8 9 10 11 12 Patient 002 001 004 003 005 20 months

12 Craig A. Dionne, PhD Chairman & CEO • Over 25 years of experience in pharmaceutical industry  SVP Drug Discovery at Cephalon, Inc. (acquired by Teva Pharmaceuticals )  EVP Prostate Cancer Foundation Peter E. Grebow, PhD Director • Over 37 years of experience in pharmaceutical industry  EVP Drug Development Cephalon, Inc.  Board member Optimer Pharmaceuticals, Q Holdings, Complexa . Bo Jesper Hansen, MD, PhD Director • Executive Chairman of Swedish Orphan Biovitrum AB  Board member CMC AB, Orphazyme ApS, Newron , TopoTarget A/S, Hyperion Therapeutics and Ablynx NV Scott Ogilvie Director • President and CEO AFIN International, Inc.  Board member Research Solutions, Inc., and Neuralstem , Inc. Russell Richerson, PhD COO • Over 25 years of experience in biotechnology industry  Previously COO Molecular Profiling Institute, VP Diagnostic R&D Prometheus, Abbott Labs Management, Directors, Advisors John T. Isaacs, PhD Chief Scientific Advisor • Professor at Johns Hopkins School of Medicine  Co - Inventor of GenSpera’s technologies Samuel R. Denmeade, MD Chief Clinical Advisor • Professor at Johns Hopkins and Board Certified Medical Oncologist  Co - Inventor of GenSpera’s technologies Søren Brøgger Christensen, PhD Scientific Advisor • Professor at University of Copenhagen. Expert in chemistry of thapsigargin  Exploring further derivatives and manufacturing efficiencies for thapsigargin Experienced Scientific and Development Team

13 GenSpera Milestones History of Milestones Achieved 2008 2009 2010 2011 2012 2013 2014 $0.7M $2.8M $4.0M $3.4M $6.2M $7.2M OTCBB listing Completed enrollment in Ph 1 Near - Term Anticipated Milestones • Initiate Phase 2 PCa trial (expected Q2 2014) • Present interim HCC data at APPLE (expected July 2014) Finalized technology license from JHU Initiated Phase 1B trial Initiated Ph 1 trial Initiated Ph 2 trial in GBM • Pilot toxicology • Pre - IND meeting • Formal toxicology • cGMP drug manufacture • Filed IND IND approved for Phase 1 clinical trials Initiated Ph 2 trial in HCC Completed Ph 1B trial

14 GenSpera Investment Profile • GenSpera is a leader in developing prodrug therapeutics for the treatment of cancer • Unique, naturally derived, cancer killing drug has advantages in potency and significantly reduced side - effects • Experienced scientific and development team • Robust global IP position • G - 202, GenSpera’s lead candidate, is showing excellent clinical results • Only a few easily managed and predictable side effects in Phase 1 • Phase 1B and early Phase 2 data in liver cancer are highly suggestive of clinical activity • Multiple development opportunities based on our prodrug platform • Four drug candidates in the pipeline • Targeting three large and deadly global cancers that currently have poor or inadequate treatment options

15 Corporate Overview April 2014 OTCQB : GNSZ